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Inflammatory responses in the kidney lead to
tubulointerstitial fibrosis, a common feature of chronic
kidney diseases. Here we examined the role of prostaglandin
E2 (PGE2) in the development of tubulointerstitial fibrosis. In
the kidneys of wild-type mice, unilateral ureteral obstruction
leads to progressive tubulointerstitial fibrosis with
macrophage infiltration and myofibroblast proliferation. This
was accompanied by an upregulation of COX-2 and PGE2
receptor subtype EP4 mRNAs. In the kidneys of EP4 gene
knockout mice, however, obstruction-induced histological
alterations were significantly augmented. In contrast, an EP4-
specific agonist significantly attenuated these alterations in
the kidneys of wild-type mice. The mRNAs for macrophage
chemokines and profibrotic growth factors were upregulated
in the kidneys of wild-type mice after ureteral obstruction.
This was significantly augmented in the kidneys of EP4-
knockout mice and suppressed by the EP4 agonist but only in
the kidneys of wild-type mice. Notably, COX-2 and MCP-1
proteins, as well as EP4 mRNA, were localized in renal tubular
epithelial cells after ureteral obstruction. In cultured renal
fibroblasts, another EP4-specific agonist significantly
inhibited PDGF-induced proliferation and profibrotic
connective tissue growth factor production. Hence, an
endogenous PGE2–EP4 system in the tubular epithelium limits
the development of tubulointerstitial fibrosis by suppressing
inflammatory responses.
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The worldwide increase in the number of patients with
chronic kidney disease and the resultant end-stage renal failure
necessitating renal replacement therapy, such as transplanta-
tion and dialysis, is threatening to reach almost pandemic
proportions.1 Tubulointerstitial fibrosis, as well as glomerulo-
sclerosis, is a major predictor of the progression to end-stage
renal failure in various types of chronic kidney disease.2 For
example, interstitial fibrosis, along with glomerulosclerosis, is
one of the most important factors determining the progression
and prognosis of diabetic nephropathy.3 In immunoglobulin A
(IgA) nephropathy, which is the most common type of chronic
glomerulonephritis characterized by glomerular IgA1 deposi-
tion, tubulointerstitial fibrosis is more closely related to
prognosis of the disease than to the glomerular damage itself.4
Therefore, clarification of the mechanism leading to tubu-
lointerstitial fibrosis is an important issue for the management
of chronic kidney disease.
Tubular epithelial cells are thought to play a pivotal role in
the process of tubulointerstitial fibrosis. These cells produce
several types of chemokines in response to various stimuli and
attract macrophages and lymphocytes into the renal inter-
stitial space.5 Among these chemokines, MCP-1 (monocyte
chemoattractant protein-1) and RANTES (regulated on
activation, T cell expressed, and secreted), which belong to
the CC chemokine family, have emerged as important
mediators of macrophage recruitment in various types of
renal diseases.6–8 The recruited macrophages induce prolifera-
tion of resident fibroblasts and their differentiation into
myofibroblasts through the production of profibrotic growth
factors, such as transforming growth factor-b1 (TGF-b1) and
connective tissue growth factor (CTGF).9,10 TGF-b1 is also
known as the main player in the phenotypic conversion of
tubular epithelial cells into mesenchymal fibroblasts, a process
known as epithelial–mesenchymal transition (EMT).11 There-
fore, tubular epithelial cells, as well as resident fibroblasts and
pericytes, are able to serve as a source of myofibroblasts.12,13
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However, recently, Humphreys et al.14 indicated no evidence
of EMT in a unilateral ureteral obstruction (UUO) model
using a novel fate-mapping technique, indicating some
arguments about the role of EMT at least in tubulointerstitial
fibrosis induced by UUO. Differentiated and activated
myofibroblasts then produce interstitial matrices and collagen
fiber, resulting in tubulointerstitial fibrosis. Although these
sequential events take place in the development of tubuloin-
terstitial fibrosis, the factors participating in the regulation of
these events have not been fully characterized.
UUO invariably induces tubulointerstitial fibrosis in the
ureter-obstructed kidney (UOK), a well-established model
used to investigate the mechanism leading to tubulointerstitial
fibrosis.8,15,16 It has been reported that prostaglandin E2
(PGE2) production increases significantly in the kidney during
the development of tubulointerstitial fibrosis induced by
UUO.17,18 However, the role of PGE2 in the development
of tubulointerstitial fibrosis remains to be determined. PGE2
exerts a variety of actions in the body by binding to its specific
rhodopsin-type receptors.19 There are four subtypes of PGE2
receptors encoded by different genes: EP1, EP2, EP3, and EP4.
EP1 couples to Gq and raises intracellular Ca
2þ concentration.
EP2 and EP4 couple to Gs and raise intracellular cAMP
concentration ([cAMP]i). Notably, EP4 has another signaling
pathway involving phosphatidylinositol 3-kinase, leading to
the activation of Akt and extracellular signal–regulated
kinases.20,21 In contrast, EP3 couples mainly to Gi and inhibits
the increase in [cAMP]i.
On the basis of the finding that the expression levels of
mRNAs for cyclooxygenase (COX)-2, a rate-limiting enzyme
of prostanoid synthesis, and EP4 were significantly upregu-
lated in the kidney after UUO, we set out to clarify the
EP4-mediated role of PGE2 in the development of tubulointer-
stitial fibrosis using mice that lack EP4 (EP4
/ mice) and
ONO-4819, a specific EP4 agonist. We found that both
endogenous PGE2 and ONO-4819 significantly suppress
UUO-induced tubulointerstitial fibrosis via EP4 in vivo. In
addition, a specific EP4 agonist ONO-AE1-329 significantly
inhibited platelet-derived growth factor (PDGF)-BB-induced
fibroblast proliferation and TGF-b1-induced EMT in vitro.
RESULTS
Renal expression levels of COX-2 and EP4 mRNAs increase
significantly in WT mice after UUO
In wild-type (WT) mice, hydronephrotic changes, including
dilation of the renal pelvis and thinning of the renal
parenchyma, occurred in UOK after UUO (Figure 1a). In
addition, these changes were accompanied by marked collagen
deposition in the renal interstitial area (Figure 1b), indicating
the development of tubulointerstitial fibrosis in the present
UUO model.
We investigated whether prostanoids and their receptor
system in the kidney respond to stress burdened by UUO in
WT mice. First, we examined the expressions of mRNAs for
COX-1 and COX-2. The expression level of mRNA for COX-2,
an inducible isoform of COX, increased significantly in UOK
on day 1 of UUO compared with that in the control kidney
and remained to a similar extent on days 4 and 7 of UUO
(Figure 1c), suggesting that COX-2-derived prostanoids play a
role in the pathogenesis of tubulointerstitial fibrosis after
UUO. Interestingly, a significant increase in the expression
level of mRNA for COX-1, a constitutive isoform of COX, was
also found in the UOK on days 4 and 7 of UUO (Figure 1c).
Next, we examined the expression levels of mRNAs for EPs
in UOK before and after UUO. Before UUO, mRNAs for all
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Figure 1 |A hydronephrotic change with interstitial fibrosis
and expression of cyclooxygenase (COX) and prostaglandin
E2 receptor (EP) mRNAs in wild-type (WT) kidneys after
unilateral ureteral obstruction (UUO). (a) A representative
photograph showing gross appearance of the kidneys on
day 7 of UUO. The ureter-obstructed kidney (UOK) exhibits a
hydronephrotic change with a dilated pelvis. (b) Sirius red–stained
coronal sections of the kidneys on day 7 of UUO. In the section
of UOK, collagen fibers stained red are evident. (c) Expression
levels of COX-1 and COX-2 mRNAs in the kidney on day 1 (d1),
day 4 (d4), and day 7 (d7) of UUO. *Po0.05 vs. respective
control. wPo0.05 vs. respective contralateral kidney (CLK); n¼ 5.
(d) Expression levels of EP mRNAs in UOK on d1, d4, and d7 of
UUO. *Po0.05 vs. respective control; n¼ 5. The amounts of
amplification products for COX-1, COX-2, and EP mRNAs were
normalized to that for 18S rRNA, and the value in control kidney
is presented as 1. Control, kidneys from nonoperated mice.
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EPs were detected. After UUO, the expression level of EP4
mRNA increased significantly and reached a level of up to
sevenfold on day 7 of UUO (Figure 1d), suggesting an EP4-
mediated role of PGE2 in the development of tubulointer-
stitial fibrosis. Although the expression level of EP2 mRNA
increased significantly to a level of up to twofold on day 7 of
UUO, those of EP1 and EP3 mRNAs did not change or
decreased significantly, respectively (Figure 1d). There were
no significant differences in the expression levels of EP4
mRNA between the upper and lower parts of the kidney
before and 7 days after UUO (data not shown).
On the basis of these results, we set out to clarify the EP4-
mediated role of PGE2 in tubulointerstitial fibrosis using the
UUO model in the following examinations.
Augmented tubulointerstitial fibrosis in EP4
/ mice and
EP4-mediated suppression of tubulointerstitial fibrosis by
ONO-4819 in WT mice
To assess the degree of fibrotic response to UUO, interstitial
collagen deposition was examined histologically in Sirius
red–stained renal sections, and hydroxyproline content was
measured for quantification of fibrosis. In the kidneys of WT
mice (WT kidneys), tubulointerstitial fibrosis developed
progressively after UUO, and renal hydroxyproline content
increased twofold over that of control kidneys on day 7 of
UUO (Figure 2a and e). In the kidneys of EP4
/ mice (EP4
/
kidneys), however, tubulointerstitial fibrosis was significantly
augmented compared with that in WT kidneys on day 7 of
UUO (Figure 2c and e), indicating that endogenous PGE2 has
a suppressive role in tubulointerstitial fibrosis via EP4.
Furthermore, when EP4 was stimulated by administration of
ONO-4819, an EP4-specific agonist, the degree of tubulointer-
stitial fibrosis in WT kidneys was significantly reduced (Figure
2d and e). In addition, the effect of ONO-4819 was completely
abolished in EP4
/ kidneys (Figure 2e), indicating that a
potent suppressive effect of ONO-4819 on tubulointerstitial
fibrosis was mediated by EP4. There was no apparent increase
in interstitial collagen deposition in the contralateral kidney
(CLK) on day 7 of UUO (Figure 2b).
Augmented macrophage infiltration and myofibroblast
proliferation in EP4
/ kidneys and suppressive effects of
ONO-4819 on these alterations
In tubulointerstitial fibrosis, macrophage infiltration is a
characteristic feature of local inflammation, and infiltrated
macrophages have a critical role in the succeeding myofibro-
blast proliferation and fibrosis.7,8,12 Therefore, we next
examined macrophage infiltration into the renal interstitial
area in the UUO model (Figure 3). In WT kidneys, UUO
induced progressive macrophage infiltration, which was noted
exclusively in the peritubular area (Figure 3a and e). This
infiltration of macrophages was detected as early as day 1 of
UUO (data not shown). In EP4
/ kidneys, however, the degree
of macrophage infiltration was significantly greater than that
in WT kidneys on days 4 and 7 of UUO (Figure 3c and e),
suggesting an EP4-mediated inhibitory effect of endogenous
PGE2 on macrophage recruitment. In addition, ONO-4819
significantly suppressed the UUO-induced macrophage
infiltration in WT kidneys, an effect absent in EP4
/
kidneys (Figure 3d and e). In control kidneys and CLKs,
a small number of macrophages were detected in the
interstitial area, but there was no significant difference in
the macrophage number between WT and EP4
/ kidneys
(Figure 3b and e).
In accordance with macrophage infiltration, UUO in-
duced a remarkable proliferation of interstitial myofibro-
blasts in WT kidneys after UUO (Figure 4a and e).
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Figure 2 |Renal interstitial fibrosis in wild-type (WT) and EP4
/
mice after unilateral ureteral obstruction (UUO). (a–d)
Representative photomicrographs of Sirius red–stained tissue
sections from WT, EP4
/, and ONO-4819-treated WT kidneys on
day 7 (d7) of UUO. Interstitially deposited collagen fibers and the
basement membrane of renal tubules were stained red. Original
magnification  400. (e) The effect of ONO-4819 on the renal
hydroxyproline content after UUO. Control (C), kidneys from
nonoperated mice. *Po0.05; n¼ 9–15. Bars¼ 20mm.
CLK, contralateral kidney; NS, not significant; UOK,
ureter-obstructed kidney.
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In EP4
/ kidneys, however, myofibroblast proliferation
was significantly augmented compared with that in WT
kidneys on days 4 and 7 of UUO (Figure 4c and e). As
anticipated, ONO-4819 significantly suppressed the UUO-
induced myofibroblast proliferation in WT kidneys, an
effect absent in EP4
/ kidneys (Figure 4d and e). In control
kidneys and CLKs, myofibroblasts could not be found in the
interstitial space (Figure 4b and e). These results indicate
that the PGE2–EP4 system negatively regulates macrophage
infiltration, thereby succeeding myofibroblast proliferation
after UUO. The results therefore suggest the involvement
of chemokine(s) for macrophages as the target molecule of
the system.
Expression levels of MCP-1 and RANTES mRNAs are
significantly higher in EP4
/ kidneys than in WT kidneys
after UUO
MCP-1 and RANTES are thought to be the major
chemokines responsible for macrophage recruitment into
the renal interstitium under inflammatory conditions.7,8
Therefore, we examined the renal expression of MCP-1
and RANTES mRNAs after UUO. In WT kidneys,
expression levels of MCP-1 and RANTES mRNAs increased
remarkably after UUO (Figure 5). In EP4
/ kidneys, however,
the expression levels of these mRNAs were significantly
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Figure 3 | Interstitial infiltration of macrophages in wild-type
(WT) and EP4
/ kidneys after unilateral ureteral obstruction
(UUO). (a–d) Representative photomicrographs of tissue sections
showing interstitial macrophage infiltration in WT, EP4
/, and
ONO-4819-treated WT kidneys on day 7 (d7) of UUO. F4/80-
positive macrophages were stained brown. Original magnification
 200. (e) Interstitial infiltration of macrophages in the kidneys
on d4 and d7 of UUO. The extent of macrophage infiltration
was expressed as interstitial macrophage number per high-power
field ( 400). *Po0.05 vs. WT mice; n¼ 5–7. Bars¼ 40mm.
CLK, contralateral kidney; HPF, high-power field; NS, not
significant; UOK, ureter-obstructed kidney.
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Figure 4 | Interstitial myofibroblast proliferation in wild-type
(WT) and EP4
/ kidneys after unilateral ureteral obstruction
(UUO). (a–d) Representative photomicrographs of tissue sections
showing interstitial myofibroblast proliferation in WT, EP4
/,
and ONO-4819-treated WT kidneys on day 7 (d7) of UUO.
Myofibroblasts positive for a-smooth muscle actin (a-SMA) were
stained brown. Original magnification  200. (e) Interstitial
myofibroblast proliferation in the kidney on d4 and d7 of UUO.
The area occupied by specifically stained myofibroblasts was
expressed as a percentage of the total area excluding the tubular
luminal area. *Po0.05 vs. WT mice; n¼ 5–7. Bars¼ 40 mm.
CLK, contralateral kidney; NS, not significant; UOK, ureter-
obstructed kidney.
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higher than those in WT kidneys on days 4 and 7 of UUO
(Figure 5), indicating an EP4-mediated suppressive
action of endogenous PGE2 on the UUO-induced
chemokine induction. Accordingly, ONO-4819 significantly
suppressed the UUO-induced renal expression of MCP-1 and
RANTES mRNAs in WT mice, an effect absent in
EP4
/ mice (Figure 5). In control kidneys and CLKs, there
were no significant differences in the expression levels
of these chemokine mRNAs between WT and EP4
/ mice.
There were no significant differences in the expression
levels of RANTES mRNA between the upper and lower parts
of the kidney before and 7 days after UUO in both
WT and EP4
/ mice (data not shown). These results indicate
that the PGE2–EP4 system indeed suppresses chemokine
induction and limits the progression of tubulointerstitial
fibrosis.
Augmented expression of TGF-b1 and CTGF mRNAs in EP4
/
kidneys after UUO
Recruited macrophages, as well as tubular epithelial cells, are
the major source of TGF-b1 and CTGF, the representative
profibrotic growth factors responsible for fibroblast prolif-
eration and for the differentiation of fibroblasts into
myofibroblasts.16,22 Because macrophage recruitment was
significantly augmented in EP4
/ kidneys, we next examined
whether renal production of these macrophage-derived
growth factors increases in EP4
/ mice after UUO. In WT
kidneys, the expression levels of TGF-b1 and CTGF mRNAs
increased remarkably after UUO (Figure 6). In EP4
/
kidneys, however, the expression level of TGF-b1 mRNA
was significantly higher than that in WT kidneys on day 7 of
UUO (Figure 6a). The expression level of CTGF mRNA in
EP4
/ kidneys was also significantly higher than that in WT
WT (+ ONO-4819)
WT
MCP-1
RANTES
NS
NS
*
*
*
*
*
*
* *
*
*
Control CLK d7 UOK d4 UOK d7
m
R
N
A/
G
AP
DH
4
3
2
1
0
m
R
N
A/
G
AP
DH
8b
a
6
4
2
0
EP4–/– (+ ONO-4819)
EP4–/–
WT (+ ONO-4819)
WT
EP4–/– (+ ONO-4819)
EP4–/–
Control CLK d7 UOK d4 UOK d7
Figure 5 | Expression of MCP-1 (monocyte chemoattractant
protein-1) and RANTES (regulated on activation, T cell
expressed, and secreted) mRNAs in the kidney after unilateral
ureteral obstruction (UUO). Expression levels of (a) MCP-1 and
(b) RANTES mRNAs in the kidney on day 4 (d4) and day 7 (d7)
of UUO. The amounts of amplification products for MCP-1 and
RANTES mRNAs were normalized to that for glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) mRNA. *Po0.05 vs.
wild-type (WT) mice; n¼ 5–7. CLK, contralateral kidney; NS, not
significant; UOK, ureter-obstructed kidney.
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Figure 6 | Expression of transforming growth factor-b1
(TGF-b1) and connective tissue growth factor (CTGF) mRNAs
in the kidney after unilateral ureteral obstruction (UUO).
Expression levels of (a) TGF-b1 and (b) CTGF mRNAs in the kidney
on day 4 (d4) and day 7 (d7) of UUO. The amounts of amplification
products for TGF-b1 and CTGF mRNAs were normalized to
that for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
mRNA. *Po0.05 vs. wild-type (WT) mice; n¼ 5–7. CLK,
contralateral kidney; NS, not significant; UOK, ureter-obstructed
kidney.
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kidneys on days 4 and 7 of UUO (Figure 6b), confirming an
EP4-mediated suppressive action of endogenous PGE2 on the
UUO-induced induction of profibrotic growth factors.
As anticipated, ONO-4819 significantly suppressed the
UUO-induced expression of TGF-b1 and CTGF mRNAs in
WT kidneys, an effect absent in EP4
/ kidneys (Figure 6). In
control kidneys and CLKs, there were no significant
differences in the expression levels of these growth factors
between WT and EP4
/ mice. These results suggest that the
PGE2–EP4 system negatively regulates the TGF-b1/CTGF axis
in the development of tubulointerstitial fibrosis by reducing
macrophage recruitment.
Expression of COX-2 and MCP-1 proteins is localized to renal
tubular epithelial cells after UUO
We next examined by immunohistochemical analysis where
the upregulation of COX-2 and MCP-1 occurs within WT
kidneys after UUO. We found intense COX-2 immunoreactiv-
ities mainly in tubular epithelial cells on day 7 of UUO (Figure
7b). Intense immunoreactivities for MCP-1 were also found
mainly in tubular epithelial cells on day 7 of UUO (Figure 7b).
Importantly, COX-2 and MCP-1 immunoreactivities were
colocalized in some tubular epithelial cells (Figure 7b). In
control kidneys, we could detect only slight immunoreactiv-
ities for COX-2 and MCP-1 (Figure 7a). These results indicate
that renal tubular epithelial cells are the major cells expressing
both COX-2 and MCP-1 after UUO and suggest that COX-
2-derived PGE2 is also produced in tubular epithelial cells.
Expression pattern of EP4 mRNA in WT kidneys after UUO
Next, we examined the expression pattern of EP4 mRNA
within the kidney after UUO by in situ hybridization analysis.
In WT control kidneys, EP4 mRNA expression was barely
detectable (Figure 8a). However, we could detect slight
signals for EP4 mRNA in the glomeruli and vascular walls of
WT control kidneys in other in situ hybridization analyses
using a radioisotope (data not shown). On day 7 of UUO,
signals for EP4 mRNA increased remarkably throughout WT
kidneys (Figure 8b). Notably, these signals were localized
mainly to tubular epithelial cells and to a lesser extent to
interstitial cells and glomeruli (Figure 8c). To further confirm
tubular localization of EP4 mRNA, E-cadherin, a representa-
tive marker for tubular epithelium, was immunostained in a
contiguous tissue section (Figure 8d). Signals for EP4
mRNAs were detected mainly in the structure that
coincides with tubular epithelium expressing E-cadherin
(Figure 8d). There were no signals for EP4 mRNA in EP4
/
kidneys on day 7 of UUO (data not shown). These results
indicate that the renal tubular epithelium is the major site
expressing EP4 after UUO, while recruited macrophages likely
express EP4.
Effects of ONO-AE1-329 on TGF-b1-induced EMT in cultured
renal tubular epithelial cells
In renal tubular epithelial cells, TGF-b1 is a representative
inducer of EMT, which was characterized by changes in the
expression of a multitude of proteins, such as a-smooth
WT Shama b WT UOK
Figure 7 | Localization of cyclooxygenase-2 (COX-2) and monocyte chemoattractant protein-1 (MCP-1) proteins in wild-type (WT)
kidneys before and after unilateral ureteral obstruction (UUO). COX-2- and MCP-1-costained sections (upper panels) and corresponding
hematoxylin and eosin–stained sections (lower panels) of the (a) control kidney and the (b) ureter-obstructed kidney (UOK) on day 7 of UUO.
Immunoreactivities for COX-2 were detected around the nuclei (red color) and those for MCP-1 within the cytosol (green color).
Bars¼ 50 mm.
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muscle actin (a-SMA), and transcription factors including
Twist, as well as morphological changes. We first examined
the effect of TGF-b1 on the expression level of EP4 mRNA in
cultured renal tubular epithelial cells isolated from WT
kidneys. TGF-b1 significantly increased the expression level
of EP4 mRNA (Figure 9a), suggesting upregulation of EP4 in
response to a proinflammatory stimulus. Next, to test
whether EP4 activation affects EMT, we examined the effect
of an EP4-selective agonist ONO-AE1-329 on the TGF-b1-
induced expression of a-SMA and Twist mRNAs in cultured
renal tubular epithelial cells. In both tubular epithelial cells
isolated from WT and EP4
/ kidneys, TGF-b1 significantly
increased the expression levels of a-SMA and Twist mRNAs
(Figure 9b and c), indicating induction of EMT. In tubular
epithelial cells from WT kidneys, ONO-AE1-329 significantly
suppressed the TGF-b1-induced expressions of a-SMA and
Twist mRNAs. In contrast, ONO-AE1-329 did not have these
effects on tubular epithelial cells from EP4
/ kidneys (Figure
9b and c), suggesting a suppressive role of the PGE2–EP4
system in EMT.
Effects of ONO-AE1-329 on PDGF-induced proliferation
of fibroblasts and TGF-b1-induced CTGF production by
fibroblasts
Next, we examined whether EP4 works also in renal
fibroblasts as well as in tubular epithelial cells. In cultured
renal fibroblasts isolated from WT kidneys, ONO-AE1-329
significantly suppressed PDGF-BB-induced proliferation in a
concentration-dependent manner (Figure 10a). In cultured
renal fibroblasts isolated from EP4
/ kidneys, however, the
suppressive effect of ONO-AE1-329 disappeared (Figure
10a). In addition, ONO-AE1-329 significantly inhibited
TGF-b1-induced CTGF production by fibroblasts isolated
from WT kidneys but not that by fibroblasts isolated from
EP4
/ kidneys (Figure 10b). These results indicate that the
PGE2–EP4 system would play a suppressive role in the
development of tubulointerstitial fibrosis after UUO acting
on fibroblasts in addition to tubular epithelial cells.
An EP4 agonist protects the kidney from folic acid–induced
renal injury
Finally, we examined whether an EP4 agonist could protect
the kidney in another model of kidney disease as well, folic
acid–induced renal injury. Blood urea nitrogen and serum
creatinine concentrations increased significantly in folic
acid–injected balb/c mice (Figure 11d and e), indicating
induction of renal injury by folic acid. ONO-4819, however,
significantly suppressed the increases in blood urea nitrogen
and creatinine concentrations (Figure 11d and e), suggesting
the protective effect of ONO-4819 in folic acid–induced renal
injury. In addition, substantial renal interstitial fibrosis was
observed after folic acid injection by histological examination
with Sirius red staining (Figure 11a and b); this fibrosis was
apparently suppressed by ONO-4819 (Figure 11c). Accord-
ingly, renal hydroxyproline content increased significantly on
day 7 of folic acid injection (Figure 11f). Notably, ONO-4819
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Figure 8 | In situ hybridization analysis of EP4 mRNA
expression in kidneys before and after unilateral ureteral
obstruction (UUO). (a, b) Hematoxylin and eosin–stained
(left panels) and the corresponding hybridized sections
(right panels) that show hybridization signals (green) for EP4
mRNA in the (a) wild-type (WT) control kidney and (b) WT
ureter-obstructed kidney (UOK) on day 7 of UUO. (c) Higher
magnifications of boxed areas in b. Arrows indicate positive
signals detected in tubular epithelial cells, and an arrowhead
indicates the signal in a glomerulus. (d) E-cadherin
immunostained (left panel) and the corresponding
hybridized (right panel) sections of WT UOK on day 7 of
UUO. E-cadherin immunoreactivities and EP4 mRNA hybridization
signals appear green. (a–d) Nuclei appear blue with 4,6-diamidino-
2-phenylindole (DAPI) staining. Bars¼ 100mm.
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significantly suppressed the increase in renal hydroxyproline
content (Figure 11f), indicating that ONO-4819 has an
antifibrotic effect also in this model.
DISCUSSION
Suppression of the development of tubulointerstitial fibrosis
has emerged as an important issue for the management of
chronic kidney diseases because it determines prognosis of
the diseases, and there is little antifibrotic therapy for
preventing the progression of chronic kidney diseases to
end-stage renal failure. Therefore, extensive research has been
conducted to clarify the mechanism of tubulointerstitial
fibrosis, and a number of signaling molecules have been
proposed to participate in the pathogenesis of this condition.
These signaling molecules, such as chemokines, inflamma-
tory cytokines, and profibrotic growth factors, mediate the
sequential events taking place during the development
of tubulointerstitial fibrosis.6,7,23 Among these mediators,
TGF-b1 and CTGF constitute an established signaling axis in
the process of tubulointerstitial fibrosis.15,22 In addition,
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Figure 10 | Effects of ONO-AE1-329 on transforming growth
factor-b1 (TGF-b1)-induced proliferation and TGF-b1-induced
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ureteral obstruction (UUO). (a) Proliferation of fibroblasts was
estimated by the nuclear incorporation of [3H]-thymidine.
*Po0.05 vs. respective control; n¼ 4–6. (b) Effect of ONO-AE1-329
on TGF-b1-induced CTGF production by fibroblasts. The
representative blots from five independent experiments are
shown in the upper panels. The expression levels of CTGF protein
were normalized to that for b-actin. C, control (no addition of
ONO-AE1-329); NS, not significant; WT, wild type. *Po0.05 vs. TGF-
b1 alone; n¼ 5.
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several factors, such as angiotensin II and bradykinin, have
been reported as upstream key molecules controlling the
events.8,10 However, the role of PGE2 as such a key molecule
remains to be determined.
In EP4
/ kidneys, tubulointerstitial fibrosis was signifi-
cantly augmented compared with that in WT kidneys after
UUO, indicating that endogenous PGE2 plays a suppressive
role in the progression of tubulointerstitial fibrosis via EP4. In
addition, when EP4 was pharmacologically activated by an
EP4-specific agonist, ONO-4819, UUO-induced tubulointer-
stitial fibrosis was significantly diminished in WT kidneys.
Furthermore, this effect was completely absent in EP4
/
kidneys, indicating that the potent suppressive effect of
ONO-4819 on tubulointerstitial fibrosis is mediated by EP4.
To our knowledge, this is the first report demonstrating that
endogenous PGE2 and an EP4 agonist exert a suppressive
action via EP4 on the development of tubulointerstitial
fibrosis in vivo.
The renal expression level of COX-2 mRNA increased
significantly after UUO, suggesting that COX-2-derived
prostanoids including PGE2 participate in the pathogenesis
of tubulointerstitial fibrosis. This result is in good agreement
with reported results that state that production of PGE2
increases significantly in the kidney after UUO.17,18,24,25 In
addition, immunohistochemical analysis showed that main
COX-2 immunoreactivities were localized to tubular epithelial
cells after UUO, suggesting that PGE2 produced by COX-2 in
tubular epithelial cells exhibits some effects on neighboring
cells, including tubular epithelial cells themselves and
interstitial cells. In addition, we found that the expression
level of EP4 mRNA increases remarkably in WT kidneys after
UUO. It has been reported that EP4 mRNA localizes mainly in
the glomeruli and the vascular wall in normal kidneys.26 After
UUO, however, the expression of EP4 mRNA was detected
mainly in tubular epithelial cells and interstitial cells. Taken
together, these results indicate that the existence of the
PGE2–EP4 system inherent in tubular epithelial cells became
apparent after UUO and suggest that the system plays a role in
the development of tubulointerstitial fibrosis by acting on
both tubular epithelial cells and interstitial cells.
Macrophage infiltration had begun as early as day 1 of
UUO before interstitial myofibroblast proliferation and
fibrosis became apparent (data not shown), as reported
previously.27 In EP4
/ kidneys, macrophage infiltration was
significantly augmented compared with that in WT kidneys
after UUO. Infiltrated macrophages are known to produce
profibrotic growth factors, such as TGF-b1 and CTGF, which
stimulate resident fibroblasts to differentiate into myofibro-
blasts that produce extracellular matrices and induce EMT,
which supplies a rich renewable source of myofibro-
blasts.10,12,28 Therefore, augmented macrophage infiltration
was suggested to be primarily responsible for the phenotypic
expression in EP4
/ mice. Ureteral obstruction exposes
tubular epithelial cells to nonimmunological stress and
induces interstitial macrophage infiltration by stimulating
the production of tubular epithelium-derived chemokines,
such as MCP-1 and RANTES.7,8 Accordingly, the expression
levels of MCP-1 and RANTES mRNAs were significantly
higher in EP4
/ kidneys than in WT kidneys after UUO. In
addition, ONO-4819 had a potent inhibitory effect on the
expression of these chemokines. Furthermore, we found that
MCP-1 expression after UUO was localized mainly in tubular
epithelial cells of WT kidneys as reported previously.29
Importantly, COX-2 and MCP-1 immunoreactivities were
colocalized in some tubular epithelial cells after UUO, whereas
these immunoreactivities were barely detectable in control
kidneys, indicating that renal tubular epithelial cells are the
major cells expressing both COX-2 and MCP-1 after UUO
and suggesting that COX-2-derived PGE2 is also produced in
tubular epithelial cells. These results indicate that PGE2 acts
on tubular epithelial cells via EP4, inhibits the chemokine
expression, and thus suppresses macrophage infiltration.
Although the role of EMT in the development of
tubulointerstitial fibrosis in vivo is questionable,14,30 we
examined the expression of EP4 mRNA and the effects of EP4
agonist to confirm the action of PGE2 via EP4 on the tubular
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epithelium using cultured renal tubular epithelial cells.
TGF-b1 could potently upregulate the expression of EP4 mRNA
in tubular epithelial cells, suggesting a mechanism of EP4
upregulation during the inflammatory process. Furthermore,
ONO-AE1-329 significantly inhibited TGF-b1-induced EMT
in cultured renal tubular epithelial cells in an EP4-dependent
manner, which agrees well with the report that PGE2 has a
potent inhibitory effect on EMT in cultured Madin-Darby
canine kidney cells.31 This result indicates that PGE2 indeed
acts on tubular epithelial cells via EP4 and affects their
function. On the other hand, several reports have presented
EP4-mediated effects of PGE2 on macrophage function. These
effects include EP4-mediated inhibitory effects of PGE2 on
lipopolysaccharide-induced expression of chemokines32,33
and inflammatory cytokines34 in cultured macrophages,
suggesting that COX-2-derived PGE2 acts also on macro-
phages and affects the course of UUO-induced tubulointer-
stitial fibrosis. However, the importance of these effects of
PGE2 on macrophage function during the development of
tubulointerstitial fibrosis in vivo remains to be determined.
Interstitial myofibroblast proliferation was significantly
augmented in EP4
/ kidneys compared with WT kidneys
after UUO. As macrophage recruitment was significantly
augmented in EP4
/ kidneys, production of macrophage-
derived growth factors that induce myofibroblast prolifera-
tion was expected to be augmented in EP4
/ kidneys after
UUO. Indeed, we found that the expression levels of TGF-b1
and CTGF mRNAs were significantly higher in EP4
/ kidneys
than in WT kidneys after UUO and that ONO-4819
exhibited a potent inhibitory effect on the expression of
these growth factors in WT kidneys. This result supports the
idea that the PGE2–EP4 system suppresses myofibroblast
proliferation after UUO by inhibiting macrophage recruit-
ment, thus decreasing the levels of macrophage-derived
growth factors. However, in vitro inhibitory effects of PGE2
on fibroblast proliferation35–38 and collagen synthesis by
fibroblasts39,40 have been reported. In addition, we showed
that ONO-AE1-329 significantly inhibited the functions of
cultured renal fibroblasts, PDGF-induced proliferation, and
TGF-b1-induced CTGF production in an EP4-dependent
manner. Therefore, these inhibitory effects of PGE2 on
fibroblast functions would partly contribute to the suppres-
sive role of the PGE2–EP4 system in the development of
tubulointerstitial fibrosis.
The PGE2–EP4 system has been suggested to have other
actions including proinflammatory41 and vascular actions.
For example, the PGE2–EP4 signaling positively regulates the
development of T helper type 1 and type 17 subsets and
determines the extent of immune inflammation.42 In relation
to the proinflammatory actions of COX-2-derived prosta-
noids, a COX-2 inhibitor etodolac has been reported to
suppress tubulointerstitial fibrosis induced by UUO.43 COX-2
and EP4 have been reported to be colocalized in the
vasculature of adult human kidney.44 However, the contribu-
tion of these proinflammatory and vascular actions to the
development of tubulointerstitial fibrosis remains to be
determined. Interestingly, ONO-4819 significantly suppressed
the development of interstitial fibrosis in folic acid–induced
renal injury. Although the precise mechanism of this action
remains to be clarified, this result further supports the idea
that the PGE2–EP4 system plays an antifibrotic role in kidney
diseases accompanied by interstitial fibrosis.
Angiotensin II has emerged as a potent fibrogenic factor
under various pathological conditions, such as cardiac
hypertrophy45 and pulmonary fibrosis.46 Mice lacking the
angiotensin II type 1a receptor have been reported to exhibit
reduced tubulointerstitial fibrosis and interstitial macrophage
infiltration after UUO,47 a phenotype that is in sharp contrast
to that of EP4
/ mice shown in this study. In addition,
angiotensin II has been reported to increase the expression of
chemokines and inflammatory cytokines, leading to activa-
tion of inflammatory cells47,48 and upregulation of TGF-b1
expression,8,10 indicating that the PGE2–EP4 system would
play an opposite role to that of the renin–angiotensin system
in the pathogenesis of tubulointerstitial fibrosis. In contrast,
mice lacking the bradykinin B2 receptor (B2/ mice) have
been reported to exhibit augmented tubulointerstitial
fibrosis after UUO.49 Although this phenotype is similar to
that of EP4
/ mice, B2/ mice had a significantly smaller
number of renal interstitial macrophages than did WT mice
after UUO, suggesting a different signaling mechanism
leading to suppression of tubulointerstitial fibrosis between
PGE2 and bradykinin. In fact, signaling of bradykinin has
been suggested to involve the activation of plasminogen
activators and the matrix metalloproteinase-2 cascade, leading
to degradation of the extracellular matrix.49 These results
indicate that two well-known inflammatory mediators, PGE2
and bradykinin, play a suppressive role in the development of
tubulointerstitial fibrosis.
In conclusion, this study clearly showed that the PGE2–EP4
system is inherent in the renal tubular epithelium that
expresses both COX-2 and EP4 in response to UUO. Thus,
the anti-inflammatory action of the PGE2–EP4 system
suppressing the tubulointerstitial fibrosis development took
place on the tubular epithelium as well, in addition to
macrophages and fibroblasts, indicating the novel role of the
tubular epithelium of utilizing the PGE2–EP4 system in the
development of tubulointerstitial fibrosis.
MATERIALS AND METHODS
Mice
The generation and maintenance of EP4
/ mice have been reported
previously.50 Most EP4
/ mice die postnatally as a result of patent
ductus arteriosus and do not survive at all in the C57BL/6
background. Therefore, F2 progenies of EP4
/ mice that survived
and their WT littermates were maintained independently in the
mixed genetic background of 129/Ola and C57BL/6.51 We could not
completely exclude the possibility that some fixation of particular
genes in WT and EP4
/ mice occurs because of selective breeding.
To minimize the fixation of particular genes, we generated
on occasion a new group of WT and EP4
/ mice by crossing
hetero mice obtained by mating of WT and EP4
/ mice. However,
we believe it necessary to consider the difference in genetic
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backgrounds, especially when examining in vivo phenotype. All
experiments, which were approved by the Asahikawa Medical
University Committee on Animal Research, were performed using
8- to 12-week-old female mice.
A model of renal interstitial fibrosis
To induce the development of renal interstitial fibrosis, UUO was
performed according to the reported method.47,49 Mice were
anesthetized with ketamine (100mg/kg intraperitoneally) and
xylazine (5mg/kg intraperitoneally) and were placed in the
abdominal position under body temperature control. The left ureter
was exposed through a small suprapelvic incision and ligated at two
sites within the middle portion with a 3/0 silk thread. The ureter was
then cut between the two ligations to prevent a retrograde infection.
At days 0, 1, 4, and 7 of UUO, the mice were killed and the kidneys
were removed. The upper half of the kidney was fixed in 4%
phosphate-buffered paraformaldehyde, followed by paraffin embed-
ding for histological and immunohistochemical examinations. The
lower half was snap-frozen in liquid nitrogen and stored at 80 1C
until use for extraction of RNA. In some experiments, the upper half
was also used for extraction of RNA to compare the expression levels
of EP4 and RANTES mRNAs between the upper and lower parts of
the kidney. When examining the effects of ONO-4819, a specific EP4
agonist for in vivo use,52 it was administered subcutaneously at a
dose of 0.1mg/kg shortly after the ureter ligation and twice a day
during the days following the experimental periods. The adminis-
tration ended a day before kidney removal. The dose used has been
shown to be effective in several in vivo models.53 ONO-4819 has a Ki
value of 0.7 nmol/l for [3H]-PGE2 binding to cloned mouse EP4 and
an EC50 value of 1.6 nmol/l for intracellular cAMP production in
Chinese hamster ovary cells expressing cloned mouse EP4.
54 ONO-
4819 was donated by Ono Pharmaceutical (Osaka, Japan). We
examined tubulointerstitial fibrosis induced in this model until day
7 of UUO, because intense fibrosis occurred thereafter, resulting in
destruction of normal tissue architecture and hindering accurate
evaluation. Because we could use limited numbers of EP4
/mice for
the experiments, and we excluded the kidneys that did not show
apparent hydronephrotic appearance, the number of mice in each
experimental group was variable as presented in figure legends.
Quantification of renal fibrosis
On day 7 of UUO or folic acid injection, the mice were killed and
the kidneys were removed. After the medulla including the pelvis
was scraped off with scissors, the remaining cortex was snap-frozen
in liquid nitrogen and stored at 80 1C until hydroxyproline assay
was performed. To estimate the degree of renal fibrosis, the
hydroxyproline content of the renal cortex was measured color-
imetrically according to the reported method.55
Histological and immunohistochemical examinations
Tissue sections of 4 mm thickness were prepared from paraffin-
embedded kidneys. For evaluation of tubulointerstitial fibrosis and
folic acid–induced renal fibrosis, the sections were stained with
Sirius red.49 For immunohistochemical examination of macrophage
infiltration and myofibroblast proliferation, deparaffinized sections
were incubated with 3% hydrogen peroxide for 10min to block
endogenous peroxidase activity. The sections were then incubated
for 30min at room temperature with their respective primary
antibodies: anti-F4/80 antibody for macrophages (T-2008; BMA
Biochemicals AG, Augst, Switzerland) and anti-a-SMA antibody for
myofibroblasts (N1584; DAKO, Glostrup, Denmark). For negative
controls, non-immune sera were used as primary antibodies. Tissue
sections were then incubated with their respective biotinylated
secondary antibodies: anti-rat IgG antibody (550327; BD PharMin-
gen, San Diego, CA) for F4/80 and anti-mouse IgG antibody
(K0677; DAKO) for a-SMA. Staining of immunocomplexes was
completed by incubating tissue sections with streptavidin–perox-
idase followed by 3,30-diaminobenzidine as a substrate, and the
sections were counterstained with hematoxylin. Under a light
microscope at  400 magnification, 10 fields within the cortical area
of each section were analyzed using Adobe PhotoShop software (San
Jose, CA) according to the reported method.49 The area occupied by
specifically stained myofibroblasts was expressed as a percentage of
the total area excluding the tubular luminal area. The degree of
macrophage infiltration was presented as the number of interstitial
macrophages per field. Costaining of MCP-1 and COX-2 was
performed in GeneticLab (Sapporo, Japan) using anti-MCP-1
(ab7202; Abcam, Cambridge, UK) and anti-COX-2 (160126;
Cayman Chemical, Ann Arbor, MI) as primary antibodies and the
Cy5- and Cy3-conjugated tyramide signal amplification system,
respectively (PerkinElmer Life and Analytical Sciences, Boston, MA).
Contiguous sections were stained with hematoxylin and eosin.
Real-time PCR analyses
Total RNA from kidney and cultured cells was isolated using Isogen
(Nippon Gene, Toyama, Japan) or an RNeasy fibrous tissue mini kit
(QIAGEN GmbH, Hilden, Germany). First-strand cDNAs were synthe-
sized using SuperScript VILO (Invitrogen, Carlsbad, CA). Real-time
PCR was performed using the TaqMan primers and probes (Applied
Biosystems, Foster City, CA) for COX-1 (Mm 00477214), COX-2
(Mm 00478374), EP1 (Mm 00443097), EP2 (Mm 00436051), EP3
(Mm 01316856), EP4 (Mm 00436053), a-SMA (Mm 00725412),
Twist (Mm 00442036), and 18S rRNA (Mm 03928990). The cycling
conditions of TaqMan primers were as follows: 10min at 95 1C,
followed by 50 cycles of 15 s at 95 1C and of 60 s at 60 1C. For the
analyses of MCP-1, RANTES, TGF-b1, CTGF, and glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH) expressions, real-time PCR
was performed using an SYBR Green assay (Roche Diagnostics,
Indianapolis, IN) as reported previously.51 The primer sets used
were as follows: 50-ACTGAAGCCAGCTCTCTCTTCCTC-30 (for-
ward) and 50-TTCCTTCTTGGGGTCAGCACAGAC-30 (reverse)
for MCP-1, 50-ATATGGCTCGGACACCACTC-30 (forward) and
50-GATGCCGATTTTCCCAGGAC-30 (reverse) for RANTES, 50-
CGGGGCGACCTGGGCACCATCCATGAC-30 (forward) and 50-
CTGCTCCACCTTGGGCTTGCGACCCAC-30 (reverse) for TGF-b1,
50-GAGTGGGTGTGTGACGAGCCCAAGG-30 (forward) and
50-ATGTCTCCGTACATCTTCCTGTAG T-30 (reverse) for CTGF,
and 50-CGGCAAGTTCAACGGCACAGTCA-30 (forward) and 50-
GGTTTCTCCAGGCGGCATGTCA-30 (reverse) for GAPDH. The
cycling conditions of SYBR Green primers were as follows: 10min at
95 1C, followed by 40 cycles of 15 s at 95 1C, 5 s at 60 1C (MCP-1,
TGF-b1, CTGF, and GAPDH) or 55 1C (RANTES), and 15 s at 72 1C.
In situ hybridization
In situ hybridization was performed in GeneticLab using Quanti-
Gene ViewRNA for the FFPE assay kit with Panomics protocols
(Affymetrix, Santa Clara, CA). Tissue sections (5 mm) were prepared
from paraffin-embedded kidneys, deparaffinized, boiled in pretreat-
ment solution, and digested with proteinase K. Sections were
hybridized for 3 h at 40 1C with a designed probe against the mouse
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EP4 (Affymetrix). Hybridized probes were amplified using PreAmp
and Amp molecules. Thereafter, multiple labeled probe oligonucleo-
tides conjugated to alkaline phosphatase were added, and FastRed
substrate was used to produce signals (red fluorophore). Nuclei were
stained with 4,6-diamidino-2-phenylindole. Contiguous sections
were also stained with hematoxylin and eosin. Staining of
E-cadherin, a typical marker for tubular epithelial cells, was
performed using an anti-E-cadherin antibody (3195; Cell Signaling
Technology, Beverly, MA) and the Cy5-conjugated tyramide signal
amplification system (PerkinElmer Life and Analytical Sciences).
A series of high-resolution monochromatic images were captured
using an automated microscope platform (PM-2000TM; HistoRx,
New Haven, CT). Images were then depicted by pseudocolor
merging with image processing software ImageJ (National Institutes
of Health, Bethesda, MD).
EMT using primary culture of mouse renal tubular epithelial
cells
Renal tubular epithelial cells were isolated from WT and EP4
/
kidneys using an antibody against Tamm–Horsfall glycoprotein
(THP), a surface marker of the thick ascending limb and early distal
convoluted tubule, and the magnetic cell sorting system (Miltenyi
Biotec, Bergisch Gladbach, Germany). Briefly, kidneys were cut into
small pieces in Hank’s balanced salt solution at 4 1C and incubated
in the same buffer containing 1mg/ml collagenase (Worthington
Biochemical, Lakewood, NJ) at 37 1C for 30min. After washing and
centrifugation, cells were incubated with anti-THP rabbit antibody
(M-20631, Santa Cruz Biotechnology, Santa Cruz, CA) for 15min.
After addition of anti-rabbit-IgG microbeads, anti-THP-antibody-
bound cells were separated by a passage through a magnet column
(Miltenyi Biotec). The collected THP-positive cells were incubated
on type I collagen–coated plates with Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum. Subconfluent cells were
serum-starved by replacing the medium with Dulbecco’s modified
Eagle’s medium containing 0.5% fetal calf serum and 1 mmol/l
indomethacin. After 24 h, the cells were incubated with 5 ng/ml
recombinant TGF-b1 (R&D Systems, Minneapolis, MN) with or
without an EP4-selective agonist ONO-AE1-329 (1mmol/l)
56 for
24 h. ONO-AE1-329 was donated by Ono Pharmaceutical. EMTwas
estimated by expression of a-SMA and Twist mRNAs using real-
time PCR.
Primary culture of mouse renal fibroblasts
Renal fibroblasts were isolated according to the reported method,57
with minor modifications. In short, kidneys on day 7 of UUO were
treated with a solution containing 1mg/ml collagenase. The released
cells were harvested and filtrated through a nylon mesh (40 mm), and
then the cells were cultured in Dulbecco’s modified Eagle’s medium
containing 10% fetal calf serum, 100U/ml penicillin, and 100mg/ml
streptomycin at 37 1C in 5% CO2.
Examination of renal fibroblast proliferation
Proliferation of renal fibroblasts was estimated by [3H]-thymidine
incorporation. The cells were plated into 24-well culture plates at
2 104 cells per well. After 48 h of culture, the culture medium was
changed to a fresh one containing 1 mmol/l indomethacin. After 24 h
of serum starvation, the cells were stimulated with 10 ng/ml PDGF-
BB (Peprotech, Rocky Hill, NJ). ONO-AE1-329 (1–1000 nmol/l) was
added 60min before the addition of PDGF-BB. After 18 h of culture,
[3H]-thymidine was added to the concentrations of 37 KBq/ml, and
the cells were cultured further for 6 h. The amount of [3H]-
thymidine incorporated into the cells was quantified using a liquid
scintillation counter.
Western blotting for CTGF
Mouse renal fibroblasts were plated into 60mm culture dishes at
2 105 cells per dish. For TGF-b1 stimulation, cells at B90%
confluence were serum-starved in Dulbecco’s modified Eagle’s
medium containing 1 mmol/l indomethacin. After 24 h of serum
starvation, cells were stimulated with 10 ng/ml of recombinant TGF-
b1. ONO-AE1-329 (100 nmol/l) was added 60min before the
addition of TGF-b1. The cells were lysed in a buffer containing
40mmol/l Tris/HCl (pH 7.5), 150mmol/l NaCl, 2mmol/l EDTA,
1mmol/l DTT, 1% Triton X-100, 2mmol/l Na3VO4, 10mmol/l NaF,
and 10mmol/l sodium pyrophosphate supplemented with a
protease inhibitor cocktail mixture (Sigma, St Louis, MO). Protein
contents were measured with a BCA Protein assay kit (Thermo
Scientific, Rockford, IL). Samples were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and then proteins were
transferred onto an Immobilon-P membrane (Millipore, Bedford,
MA). After a blocking procedure, the membrane was incubated
overnight with anti-CTGF (ab6992; Abcam) or anti-b-actin (Clone
AC-15; Sigma) antibody at 4 1C, followed by incubation with a
secondary antibody coupled to horseradish peroxidase. After
washing, the amount of CTGF or b-actin protein was detected by
enhanced chemiluminescence (GE Healthcare, Little Chalfont, UK).
Signals of these blots were visualized using an LAS-3000 image
analyzer (Fuji Photo Film, Tokyo, Japan).
Folic acid–induced renal injury
On day 0 of the experiments, folic acid was administered
intraperitoneally at a dose of 250mg/kg to 8-week-old male balb/c
mice.58 ONO-4819 was administered subcutaneously at a dose of
0.1mg/kg twice a day from days 0 to 6 of the experiments. To assess
renal function, blood urea nitrogen and serum creatinine concen-
trations were measured using assay kits (DIUR-500 and DICT-500;
BioAssay Systems, Hayward, CA) on day 7 of the experiment. The
kidneys were then removed, and the renal hydroxyproline content
was determined as described.
Statistical analyses
All values are expressed as means±s.d. The comparison of more than
two groups was analyzed with one-way analysis of variance followed
by Bonferroni’s test. For comparison of two groups, Student’s t-test or
the Mann–Whitney test was conducted after carrying out the F-test
for equal variance. Po0.05 was considered statistically significant.
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